1. In this study of patients undergoing PET myocardial perfusion imaging, those with greater measured ischemia had improved overall and cardiac survival with early revascularization compared to medical therapy alone.
2. An ischemia threshold of 5% was determined, above which patients were observed to have greater benefit with early coronary revascularization compared to pharmacotherapy.
Evidence Rating Level: 2 (Good)
Study Rundown: For patients with stable coronary artery disease the use of invasive revascularization has not demonstrated any survival or cardiovascular benefit compared to standard medical management. Identifying high-risk patients through myocardial perfusion imaging (MPI) has been one proposed strategy for selecting individuals who may benefit from coronary revascularization. Positron emission tomography (PET) use in MPI evaluation has improved image resolution, lower radiation exposure, improved diagnostic accuracy, and shorter acquisition time compared to standard imaging techniques. The current study sought to evaluate whether PET MPI may identify patients who would benefit from revascularization compared to medical management in a modern cohort. The study found that significant ischemia on PET MPI predicted improved overall and cardiovascular mortality with early revascularization with a threshold ischemia level of 5%.
The current study supports the use of PET MPI for selecting patients at risk for death or major adverse cardiovascular events and suggests a threshold potential ischemia value for which revascularization may be considered. The study is hypothesis generating and results should be confirmed in prospective studies. The main strength of the study is the large contemporary cohort of consecutively undergoing standardized PET MPI testing. The limitations of the study include the single-center, observational design which may influence the outcome with selection bias.
©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.